Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 9/20 | 0.53 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.42 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | PRKDC | P78527 | 2/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | BMI1 | P35226 | 1/20 | 0.33 |
| ▸ | MAP3K14 | Q99558 | 5/20 | 0.33 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12001480 | 0.87 | PAK4 (0.41) | PAK4KCNH2PRKDCBMI1MAP3K14 | |
| SCHEMBL12001271 | 0.86 | PAK4 (0.70) | PAK4PAK1PKN1KCNH2PRKDC | |
| SCHEMBL12001462 | 0.86 | PAK4 (0.70) | PAK4PAK1PKN1KCNH2PRKDC | |
| SCHEMBL11971176 | 0.84 | PAK4 (0.77) | PAK4PAK1PKN1MAP3K14 | |
| SCHEMBL11970503 | 0.84 | PAK4 (0.77) | PAK4PAK1PKN1MAP3K14 | |
| SCHEMBL12001506 | 0.81 | PAK4 (0.53) | PAK4PAK1PKN1KCNH2PRKDC | |
| SCHEMBL12001496 | 0.80 | PAK4 (0.55) | PAK4PAK1PKN1DHFRBMI1 | |
| SCHEMBL12001581 | 0.74 | MAP3K14 (0.56) | PAK4PAK1PKN1KCNH2PRKDC | |
| SCHEMBL11970464 | 0.73 | PAK4 (0.41) | PAK4PAK1PKN1DHFRBMI1 | |
| SCHEMBL12001779 | 0.73 | MAP3K14 (0.46) | PAK4DHFRBMI1MAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012123522-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
| US-20120214762-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | GENENTECH, INC. (US) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214762-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | NFKB1, NFRKB, NFKBIA | PAK4 1856/4885PAK1 1017/4885PKN1 1987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.